ArticleMedicine and science in sports and exercise2026
When Size Goes Inside: Visceromegaly in Bodybuilders Is Not Attributed to High-Protein Intake but More Likely Associated with the Use of Appearance- and Performance-Enhancing Drugs.
Article in Medicine and science in sports and exercise, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBodybuilders use progressive resistance exercise training and high-protein-intake diets to develop muscular physiques. Some also use appearance- and performance-enhancing drugs (APED) to further enhance their physique. It has been speculated that a high-protein intake and APED use may induce visceral organ hypertrophy. Therefore, the primary objective of this study was to assess visceral organ volumes in natural and APED-using male bodybuilders and to compare these with recreationally active males (CON).
methodsMagnetic resonance imaging (MRI) was applied to assess skeletal muscle and visceral organ volume in 15 CON (age: 29 ± 6 y), 15 competitive male natural bodybuilders (BB-NAT; age: 30 ± 5 y), and 15 competitive male APED-using bodybuilders (BB-USE; age: 31 ± 4 y). In addition, dual-energy X-ray absorptiometry (DXA) was performed to assess total body lean mass. All participants reported their habitual food intake (via 7-d food diary) and, if applicable, their use of APED.
resultsHabitual protein intake was much higher in the bodybuilders (BB-NAT: 2.5 ± 0.6 g/kg body mass (BM)/d; BB-USE: 2.9 ± 0.4 g/kg BM/d) compared with CON (1.4 ± 0.3 g/kg BM/d; P < 0.001), with no differences between both bodybuilder groups ( P = 0.109). Total lean BM was significantly different across all groups and was greater in BB-USE (87.8 ± 8.0 kg) versus BB-NAT (72.7 ± 6.4 kg) versus CON (62.8 ± 4.8 kg; P < 0.001). Muscle volumes were also different between groups, with average thigh muscle volumes of 7.1 ± 1.0, 5.8 ± 0.7, and 4.5 ± 0.4 L in BB-USE, BB-NAT, and CON, respectively ( P < 0.001). All visceral organ volumes were greater in BB-USE compared with BB-NAT and CON ( P < 0.05), with no differences between BB-NAT and CON ( P > 0.05). Heart volume averaged 1.20 ± 0.15, 0.89 ± 0.14, and 0.83 ± 0.15 L in BB-USE, BB-NAT, and CON, respectively. Liver volume averaged 2.57 ± 0.39, 1.82 ± 0.20, and 1.79 ± 0.21 L, respectively.
conclusionsDespite higher habitual protein intake and greater lean BM, natural bodybuilders do not show greater visceral organ volumes compared to age-matched controls. Bodybuilders using APED show substantially greater lean mass, muscle mass, as well as greater visceral organ volumes, compared with natural bodybuilders or age-matched controls. We conclude that visceromegaly in bodybuilders cannot be attributed to a high-protein intake but is secondary to the use of APED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.